Could cause temporary or reversible harm; serious harm is unlikely.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
| Brand name | VALSARTAN AND HYDROCHLOROTHIAZIDE |
| Generic name | VALSARTAN AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, VALSARTAN |
| Distributed by / for | Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A |
| NDC | 0378-6323-77 |
| Full product label | Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg, (a) 90-count bottle (NDC 0378-6323-77), (b) 500-count bottles (NDC 0378-6323-05), Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A. |
| Recalling firm | Mylan Laboratories Limited, (Nashik FDF) |
| Distribution | Product was distributed throughout the United States to several major distributors, including Puerto Rico. |
| Quantity | 22,813 HDPE bottles |
| Recall initiated | 2018-12-04 |
| Report date | 2018-12-19 |
| Recall completed | — |
| Recall number | D-0330-2019 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Sinnar, Nashik District N/A India |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗